Press Releases

Health News Posted on Sunday, November 24, 2019

Premium Press Releases »

ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)

A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer.  Earlier this year, scientists from Columbia University in New York demonstrated that the growth rate of pancreatic ...

Read More

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

SAN ?WANN, Malta, June 13, 2024 (GLOBE NEWSWIRE) -- Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU. As a bioequivalent version of Victoza ® pre-filled pen, ...

Read More

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy

TAIPEI, Taiwan, June 12, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast ...

Read More

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy ...

Read More

Press Releases »

Business Benefits Group Consultant Accepted Into Health Rosetta Associate Advisor Program

Benefits Advisor at Business Benefits Group was accepted into the Health Rosetta Associate Advisor Program. FAIRFAX, Va. , Nov. 24, 2019 /PRNewswire-PRWeb/ -- Jessica Du Bois, an employee benefits consultant at Business Benefits Group, was ...

Read More

Dosing of first patient in phase 3 pivotal study of sovateltide (PMZ-1620), a first-in-class investigational product, for acute cerebral ischemic stroke

WILLOWBROOK, Ill. , Nov. 23, 2019 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced the initiation of dosing in ...

Read More
More Press Releases

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.